Introduction {#s1}
============

Oropharyngeal candidosis (OPC) is the most prevalent and recurrent opportunistic infection in acquired immune deficiency syndrome (AIDS) patients and often indicates the presence of human immunodeficiency virus (HIV) infection and its progression (Li et al., [@B27]). According to Flint et al. ([@B12]), OPC meets the criteria to serve as a useful marker for both the restoration of immune functions and HIV disease progression following highly active antiretroviral therapy (HAART) failure, because it is not gender- or race-specific, it occurs early in immune dysfunction in the erythematous form, and its prevalence correlates with the HIV viral load. Although the occurrence of OPC has declined following the introduction of anti-retroviral therapy (ART), it remains a substantial problem for patients in resource-limited locales or among individuals who develop mycological resistance or have a poor immunologic response (Thompson et al., [@B56]).

OPC denotes candidosis of the mouth and throat; when the disease involves the esophagus, it is termed esophageal candidosis or candida esophagitis (Centers for Disease Control and Prevention, [@B9]). OPC inevitably occurs in \~80--90% of HIV patients in the primary, asymptomatic, or overt phases of the disease (Vazquez, [@B59]). It primarily manifests as a superficial mucosal infection in the form of pseudomembranous, erythematous, or angular cheilitis in HIV-positive individuals. The chronic atrophic candidosis (denture stomatitis) variant is often seen in the aging HIV-infected population due to their improved survival. Manifestations in the form of kissing lesions (concomitant lesions on the tongue and palate) can also be pathognomonic presentations of HIV-associated candidiasis. Patients complain chiefly of pain and a burning sensation in the mouth and an altered (cotton-like) taste sensation. Extensive involvement of the esophagus often leads to pain and difficulty in swallowing, eventually resulting in esophageal candidosis (Thompson et al., [@B56]; Cassone and Cauda, [@B7]).

The detailed pathogenesis underlying the predisposition of HIV-infected patients for OPC is unclear. Evidence provided by several studies indicates that pathogenic *Candida* colonization in an uninfected individual is shielded by a concerted contribution of oral keratinocytes, immune cells, and salivary constituents; thus, multiple rather than single defects in the host defense mechanism seem to increase the risk of OPC in HIV patients (Repentigny et al., [@B42]). Moreover, *C. albicans* is hypothesized to form complex biofilms on both mucosal and abiotic surfaces, such as dentures, and can efficaciously co-exist with oral commensal bacteria and host cells (Dongari-Bagtzoglou et al., [@B10]; Harriott and Noverr, [@B16]). *Candida*-bacterial biofilms have been proposed to have an increased likelihood of resistance to routine anti-fungal agents and are challenging to treat, especially in patients with oral prosthetic appliances (Jenkinson and Douglas, [@B18]; Nett et al., [@B36]).

HAART regimens have changed the prognosis of AIDS from a fatal condition to a chronic disease with a decent life expectancy. The use of HAART improves immunological functions and suppresses the viral load, thereby aiding in the decline of the majority of opportunistic infections, including OPC (Vazquez, [@B58]; Tamí-Maury et al., [@B52]). Nonetheless, the epidemiology of OPC in the present era of ART is not well-established. Furthermore, an epidemiological shift of the common pathogen *C. albicans* to resistant *C. albicans* and the rise in intrinsically resistant non-*C. albicans Candida* (NCAC) species has been acknowledged despite the judicious use of fluconazole, which is the chief azole anti-fungal drug used to treat primary OPC cases in HIV-infected patients (Patel et al., [@B37]; Berberi et al., [@B6]).

Thus, with the above outlook, the present narrative review emphasizes the changing *Candida* profiles and the subsequent challenges in the diagnosis and management of OPC in HIV-positive patients.

Method
------

A web-based search was performed via the PubMed database with the keywords OPC, epidemiology, prevalence, HIV/AIDS, *Candida* biofilm, anti-fungal resistance, diagnosis, and management. Original research (2007--2017, studies involving epidemiological data stating OPC, patients on/off ART and anti-fungal with/without symptomatic OPC), reviews, case reports and short communications published in the English language were included to appraise various topics. The findings are noted in the following sub-sections, followed by a discussion under the current therapeutic challenges section.

*Candida* profile in aids patients in the post-haart era {#s2}
========================================================

Epidemiology of OPC over the past decade
----------------------------------------

The selected studies (Table [1](#T1){ref-type="table"}) revealed that the prevalence of OPC ranged from 0.9 to 83% (Adedigba et al., [@B2]; Nadagir et al., [@B35]; Fabian et al., [@B11]; Thompson et al., [@B56]; Tamí-Maury et al., [@B52]; Patel et al., [@B37]; Kwamin et al., [@B26]; Maurya et al., [@B30]; Mulu et al., [@B34]; Berberi et al., [@B6]; Kirti et al., [@B24]; Das et al., [@B8]; Konaté et al., [@B25]; Terças et al., [@B54]). The reported studies from African populations showed that the prevalence of OPC ranged from 0.9 to 81.5% (Adedigba et al., [@B2]; Fabian et al., [@B11]; Kwamin et al., [@B26]; Mulu et al., [@B34]; Konaté et al., [@B25]). The studies from the Indian sub-continent showed that the prevalence of OPC ranged from 5.0 to 38.8% (Nadagir et al., [@B35]; Maurya et al., [@B30]; Kirti et al., [@B24]; Das et al., [@B8]).

###### 

Occurrence of OPC in AIDS patients.

  **S. No**.   **Author, Year**            **Region**           **Sample size**   **OPC cases (%)**                **On ART**                  **On Anti-fungal**
  ------------ --------------------------- -------------------- ----------------- -------------------------------- --------------------------- --------------------
  1\.          Terças et al., [@B54]       Brazil               52                43 (83%)                         Few                         Few (52.2%)
  2\.          Konaté et al., [@B25]       Cote d\'Ivoire       286 (281 HIV+)    227 (79.4%)                      88.5%                       No
  3\.          Das et al., [@B8]           India                141               27 (19.1%)                       No                          Few (17/141)
  4\.          Berberi et al., [@B6]       Lebanon              50                38 (76%)                         Yes                         Not mentioned
  5\.          Kirti et al., [@B24]        India                100               20 (20%)                         75/100                      Not mentioned
  6\.          Kwamin et al., [@B26]       Ghana                267               66 (81.5%) 147 (79%)             Yes (81/267) No (186/267)   No
  7\.          Mulu et al., [@B34]         Northwest Ethiopia   221               82 (37.5%)                       Yes                         Few
  8\.          Maurya et al., [@B30]       India                190               16/90 (17.8%) 5/100 (5.0%)       No Yes                      No
  9\.          Patel et al., [@B37]        Texas                215               59 (27%)                         30/59                       Few (79/215)
  10\.         Tamí-Maury et al., [@B52]   Alabama              375               281 (74.9%)                      Few                         Not mentioned
  11\.         Thompson et al., [@B56]     Texas                122               99 (81.1%) (33.3% symptomatic)   Yes                         Yes
  12\.         Fabian et al., [@B11]       Tanzania             187               12 (6.4%)                        No                          Not mentioned
  13\.         Nadagir et al., [@B35]      India                340               132 (38.8%)                      Yes                         Yes
  14\.         Adedigba et al., [@B2]      Nigeria              225               2 (0.9%)                         No                          Not mentioned

Prevalent *Candida* species
---------------------------

The collected data from the relevant studies (Table [2](#T2){ref-type="table"}) conducted over the past decade depicted *C. albicans* as the most prevalent *Candida* species (37.2--95.2%) in HIV patients with OPC. *C. glabrata, C. tropicalis, C. parapsilosis, C. krusei*, and *C. dubliniensis* were found in decreasing order among the NCAC species. *C. glabrata* (0.99--23.0%) and *C. tropicalis* (1.2--12%) were invariably found with *C. albicans* in most studies (Nadagir et al., [@B35]; Thompson et al., [@B56]; Patel et al., [@B37]; Kwamin et al., [@B26]; Maurya et al., [@B30]; Mulu et al., [@B34]; Sharifzadeh et al., [@B49]; Ho et al., [@B17]; Berberi et al., [@B6]; Katiraee et al., [@B20]; Menezes et al., [@B32]; Das et al., [@B8]; Konaté et al., [@B25]; Terças et al., [@B54]). *C. dubliniensis* was found relatively more often in two of the Indian studies and two studies from Texas (Nadagir et al., [@B35]; Thompson et al., [@B56]; Patel et al., [@B37]; Das et al., [@B8]).

###### 

Isolation and frequency of different *Candida* species with respect to OPC in HIV-positive patients.

  **S. No**.         ***Candida* species**                           **Frequency of isolates (%)**                                                                                                                                                                                                                                                                               
  ------------------ ----------------------- ----------------------- ------------------------------- ------------------------ ----------------------- ------------------------- ------------------- ----------------------- ----------------------- ---------------------------- --------------------- ---------------------- ------------------------- ------------------------ ------
  1\.                *C. albicans*           56                      95.2                            77.0                     67.6                    92.0                      60                  74.0                    68.50                   90.5                         37.2                  46.0                   62                        54                       66.6
  2\.                *C. glabrata*           8                       1.3                             3.2                      4.5                     2.6                       23                  6.5                     0.99                    4.8                          19.4                  5.6                    17                        16                       --
  3\.                *C. tropicalis*         12                      2.2                             --                       7.2                     5.3                       5                   4.5                     7.39                    1.2                          6.9                   7.0                    5                         6                        8.9
  4\.                *C. parapsilosis*       4                       0.4                             3.2                      9.0                     --                        3                   1.9                     2.96                    --                           6.5                   --                     1                         2                        11
  5\.                *C. krusei*             12                      --                              --                       3.6                     --                        2                   --                      6.40                    1.1                          7.3                   0.009                  2                         3                        20
  6\.                *C. dubliniensis*       --                      --                              14.7                     2.7                     --                        5                   6.5                     1.48                    --                           7.7                   --                     12                        17                       48.9
  7\.                *C. kefyr*              --                      --                              --                       1.8                     --                        2                   --                      0.49                    2.4                          --                    --                     --                        --                       --
  8\.                *C. famata*             4                       --                              1.6                      0.9                     --                        --                  0.6                     0.99                    --                           --                    --                     --                        --                       --
  9\.                *C. guilliermondii*     4                       --                              --                       0.9                     --                        --                  1.9                     0.99                    --                           2.0                   --                     --                        0.5                      4.9
  10\.               *C. lusitaniae*         --                      --                              --                       0.9                     --                        --                  --                      0.99                    --                           2.0                   --                     --                        1                        --
  11\.               *C. sake*               --                      --                              --                       --                      --                        --                  --                      2.46                    --                           --                    --                     --                        --                       --
  12\.               *C. stellatoidea*       --                      --                              --                       --                      --                        --                  --                      --                      --                           --                    --                     --                        --                       6.7
  **Author, Year**   Terças et al., [@B54]   Konaté et al., [@B25]   Das et al., [@B8]               Menezes et al., [@B32]   Berberi et al., [@B6]   Katiraee et al., [@B20]   Ho et al., [@B17]   Kwamin et al., [@B26]   Maurya et al., [@B30]   Sharifzadeh et al., [@B49]   Mulu et al., [@B34]   Patel et al., [@B37]   Thompson et al., [@B56]   Nadagir et al., [@B35]   

Mixed *Candida* colonization
----------------------------

Mixed colonization by various NCAC species together with *C. albicans* has been reported to occur in 23.7% of cases (Mulu et al., [@B34]). Ho et al. ([@B17]) reported that among the 45% of HIV outpatients colonized by yeasts, 16.5% harbored more than one species. Similarly, Menezes et al. ([@B32]) reported that 77.5% of the cases had *Candida* colonization by a single species, whereas 22.5% of the cases had a combination of two or more species. In another study, 7 of the 43 considered patients had double colonization (Terças et al., [@B54]).

Anti-fungal-resistant *Candida* species
---------------------------------------

In several of the studies, the frequency of fluconazole-resistant *C. albicans* was reported to be 9.3, 12.2, 16, 17.6, 25.97, and 56.7%, whereas the frequency of fluconazole-resistant *C. glabrata* was reported to range from 50 to 52% (Nadagir et al., [@B35]; Mulu et al., [@B34]; Ho et al., [@B17]; Katiraee et al., [@B20]; Rosana et al., [@B43]; Salari et al., [@B45]; Terças et al., [@B54]). *C. glabrata* possesses the ability to develop resistance to fluconazole after exposure, whereas *C. krusei* has innate resistance to this anti-fungal agent (Terças et al., [@B54]). Similarly, *C. lusitaniae* exhibits a unique tendency to readily develop resistance to anti-fungal agents, such as fluconazole, amphotericin B, and flucytosine (Zhang et al., [@B61]).

*Candida* colonization and CD4+ cell counts
-------------------------------------------

Several studies have shown a significant correlation between CD4+ T lymphocytes and *Candida* colonization. A lower count, especially below 200 CD4+ cells with or without statistical significance has been frequently associated with the increased occurrence of OPC (Tamí-Maury et al., [@B52]; Maurya et al., [@B30]; Ho et al., [@B17]; Berberi et al., [@B6]; Kirti et al., [@B24]; Menezes et al., [@B32]; Das et al., [@B8]; Konaté et al., [@B25]). The Th17 cell functional subset within the CD4+ T cell lineage seems to be selectively depleted with the progression of HIV infection and appears to be the critical host determinant of the ability of *C. albicans* to overwhelm epithelial defenses and cause disease (Cassone and Cauda, [@B7]).

*Candida* colonization and viral load
-------------------------------------

The data on the association between the plasma HIV RNA level and OPC differ and are not conclusive (Li et al., [@B27]). Only a few recently conducted studies have shown a correlation between high viral loads and an increased frequency of OPC in HIV-infected patients (Tamí-Maury et al., [@B52]; Ho et al., [@B17]; Terças et al., [@B54]).

*Candida* biofilm
-----------------

Complex oral *Candida* biofilms have been reported to be comprised of fungal, bacterial and host cells or cell-derived products (Dongari-Bagtzoglou et al., [@B10]). An *in vivo* study in rats demonstrated that the *Candida* biofilms associated with dentures were more resistant to common anti-fungal drugs and showed a relatively mixed-species colonization (Nett et al., [@B36]). The interactions between one common commensal of the oral cavity (*Streptococcus gordonii*) and *C. albicans* has been suggested to influence the development of biofilms via physical (adherence) and chemical (diffusible) signals (Harriott and Noverr, [@B16]).

Current therapeutic challenges {#s3}
==============================

The interpretations of the above findings from recent studies on OPC in HIV patients are as follows:

Art impacts the occurrence of OPC in AIDS patient, but OPC is still prevalent in the present era in a varying range (0.9--83%)
------------------------------------------------------------------------------------------------------------------------------

Protease inhibitors (PI) were the earliest anti-retrovirals proposed to be linked to a decreased rate of OPC in AIDS patients (Ho et al., [@B17]). The HIV proteinase inhibitors in the PI-HAART cocktail impede *Candida* SAP (HIV proteinases share an elevated sequence homology with *C. albicans* SAP), resulting in an initial dramatic reduction in OPC (Cassone and Cauda, [@B7]). The reduction of OPC following PI-HAART is also attributed to immune reconstitution, as measured by the elevation of circulating CD4+ T cells (CD4) and the reduction of the viral load (Tamí-Maury et al., [@B52]).

The studies quoted in Table [1](#T1){ref-type="table"} state the prevalence of OPC, but very few of these studies mention clear inclusion and exclusion criteria, which are essential for true determination of the impact of ART on OPC. The studies conducted by Konate et al., Kwamin et al., and Maurya et al. clearly defined the selected HIV-positive patients and their anti-fungal and ART statuses. The findings of Konaté et al. ([@B25]) revealed a high prevalence of OPC (79.4%) despite the patients undergoing ART. These authors suggested this finding might have occurred because PIs were not used as a first line of ART in Côte d\'Ivoire, the majority of the patients had CD4+ cell counts below 200 and a high proportion of the patients were under concurrent tuberculosis treatment regimens with rifampicin. Kwamin et al. and Maurya et al. divided the HIV-positive patients into two groups (i. e., the first under HAART and the second without a HAART regimen). The difference in the prevalence of OPC among the two groups was insignificant in the study of Kwamin et al. ([@B26]). Conversely, Maurya et al. ([@B30]) reported an interesting finding; although a significant difference was noted in the OPC occurrence, ART did not affect *Candida* colonization between the two groups. Similarly, Thompson et al. ([@B56]) observed high yeast colonization (81.1%) and low symptomatic OPC infection (33.3%) in HIV-positive patients undergoing ART and anti-fungal treatment. Thus, ART appears to decrease the symptomatic manifestation of OPC rather than *Candida* colonization.

Another explanation for the prevalence of OPC may be HIV-IRIS (HIV-associated immune reconstitution inflammatory syndrome), which usually manifests within the first 6 months of ART initiation. This disorder refers to a pathological inflammatory response that is typically directed toward microbial antigens due to immune recovery following the commencement of ART. Two distinct patterns of the disorders have been recognized: "paradoxical IRIS" (wherein the signs and symptoms of a diagnosed opportunistic infection worsen acutely despite receiving treatment with a favorable response) and "unmasking IRIS" (wherein a new opportunistic infection with a pronounced inflammatory component develops). OPC is suggested to be a likely manifestation of the unmasking type of HIV-IRIS (Walker et al., [@B60]). Nonetheless, limited studies have investigated the oral opportunistic lesions associated with HIV-IRIS. Ramírez-Amador et al. ([@B41]) and Gaitan Cepeda et al. ([@B13]) reported that OPC was a distinct manifestation of this syndrome. Achenbach et al. ([@B1]) reported that *Candida* esophagitis was a consequence of paradoxical IRIS.

Although *C. albicans* is the most common opportunistic pathogen, NCAC species, especially *C. glabrata* and *C. tropicalis*, together with mixed species colonization are significantly reported
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*C. glabrata* is the most common NCAC species isolated from HIV-positive patients, as evidenced from Table [2](#T2){ref-type="table"}. Exposure to anti-fungal agents during treatment of candidosis may provide positive selection pressure for NCAC species, such as *C. glabrata* and *C. krusei*, which are considered intrinsically less sensitive than other species to anti-fungal agents, thereby increasing their prevalence (Pfaller, [@B40]). Furthermore, mixed *C. albicans* and *C. glabrata* co-infections are more challenging to treat. Alves et al. ([@B3]) investigated *in vitro* co-infection by *C. albicans* and *C. glabrata* in a reconstituted human vaginal epithelium and observed higher tissue damage in the co-infection compared to the single *C. albicans* infection. Recently, Tati et al. ([@B53]) demonstrated that *C. albicans* aided in both the initial colonization and establishment of OPC infection by *C. glabrata*, which was suggestive of a synergistic relationship. Interactions between *C. albicans* and other NCAC species have been investigated, and *C. dubliniensis* and *C. krusei* have been observed to suppress *C. albicans* populations in biofilms. However, both *in vivo* and *in vitro* study models have shown that single infections by *C. albicans* are more harmful than mixed infections with *C. albicans---C. glabrata* or *C. albicans---C. krusei* (Rossoni et al., [@B44]).

Resistant *Candida* species are frequently associated with AIDS
---------------------------------------------------------------

Acquired resistance is uncommon but has been reported to be escalating at present (Cassone and Cauda, [@B7]; Pfaller, [@B40]; Sanguinetti et al., [@B47]). The collected data show that the frequency of resistant *C. albicans* in HIV-positive patients ranges from 9.3 to 56.7% (Nadagir et al., [@B35]; Mulu et al., [@B34]; Ho et al., [@B17]; Katiraee et al., [@B20]; Rosana et al., [@B43]; Salari et al., [@B45]; Terças et al., [@B54]). Acquired resistance to fluconazole is mainly attributed to repeated and prolonged exposure or suppressive courses of low doses of the drug combined with severe immune suppression (Patton et al., [@B39]; Lortholary et al., [@B29]; Liu et al., [@B28]). Patient compliance is another vital factor that may shroud the true reflection of a drug\'s efficacy (Patton et al., [@B39]). Furthermore, to adapt to various host niches under stressful conditions, *C. albicans* regulates gene expression and biochemical activities according to cellular needs by engendering genetically altered variants as an adaptive response to the changing host environment and new niches, thereby endowing it with anti-fungal drug resistance (Hampe et al., [@B15]).

Cross-resistance refers to non-susceptibility to several drugs of the same class. For example, specific FKS1 mutations in *C. albicans* produce cross-resistance to all echinocandins. Multi-drug resistance refers to simultaneous resistance to at least two different classes of anti-fungal agents. Loss-of-function mutations in ERG3 in *C. albicans* and *C. dubliniensis* have been reported to result in simultaneous multi-drug resistance to azoles and amphotericin B (Sanglard, [@B46]). Mulu et al. ([@B34]) reported cross-resistance in 9 *Candida* isolates from OPC patients with AIDS that were resistant to fluconazole and concurrently were found to be resistant to ketoconazole (2 isolates) and itraconazole (5 isolates). The combined overexpression of CDR2 and ERG11 and a mutation in the ERG11 gene were found to be a genetic mechanism of fluconazole resistance in *C. albicans* isolated from HIV patients in Indonesia (Rosana et al., [@B43]). Brief descriptions of the resistance mechanisms of important classes of anti-fungal agents have been compiled in Table [3](#T3){ref-type="table"} (Kanafani and Perfect, [@B19]; Pfaller, [@B40]; Vandeputte et al., [@B57]; Morace et al., [@B33]; Patil et al., [@B38]; Sanguinetti et al., [@B47]; Sanglard, [@B46]; Hampe et al., [@B15]).

###### 

Major classes of anti-fungal drugs and mechanism of resistance in *Candida* species (Kanafani and Perfect, [@B19]; Pfaller, [@B40]; Vandeputte et al., [@B57]; Morace et al., [@B33]; Patil et al., [@B38]; Sanguinetti et al., [@B47]; Sanglard, [@B46]; Hampe et al., [@B15]).

  **Anti-fungal**     **Mechanism of action**                                                                                                                                                                                                                            **Mechanism of resistance development**
  ------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Azoles              Inhibit the target enzyme lanosterol 14-a-sterol demethylase, which aids in the conversion of lanosterol to ergosterol (an important component of the fungal cell membrane), resulting in accumulation of the toxic product 14-a-methyl-3,6-diol   Development of active efflux pumps (facilitated by up regulation of the CDR1, CDR2 and MDR1 genes)Prevents binding to the target enzyme lanosterol C14a-demethylase site (mutations in the ERG11 gene)Target enzyme up-regulation (higher intracellular ERG11p concentrationsPrevents the formation of 14a-methyl-3,6-diol (a toxic product) from 14a-methylfecosterol and enables functional membranes (mutation of the ERG3 gene)Gain of function mutations in Mrr1, Tac1 and Upc2 (zinc cluster transcription factors)
  Polyenes            Formation of porin channels leading to loss of transmembrane potential and impaired cellular function                                                                                                                                              Defects in the ERG3 geneIncreased catalase activity
  Echinocandins       Inhibit the synthesis of b-1,3-D glucan, which is an integral component of the fungal cell wall                                                                                                                                                    Point mutations in the Fks1 geneIncrease in chitin synthesis in *Candida* speciesParadoxical effect
  Pyrimidine analog   Inhibits cellular DNA and RNA synthesis                                                                                                                                                                                                            Mutation in cytosine permeaseDefects in flucytosine metabolism through mutations in cytosine deaminase or uracil phosphoribosyl transferase (FUR1 gene mutations)

Candida biofilms are more resistant to treatment
------------------------------------------------

The key aspect of *C. albicans* pathobiology is formation of a biofilm, which is regulated by six transcription factors (Bcr1, Brg1, Efg1, Ndt80, Rob1, and Tec1; Glazier et al., [@B14]). *Candida* is also known to form mixed-bacteria or polymicrobial biofilms that are capable of surviving many external challenges; for example, mixed biofilms containing *C. albicans* and *Streptococcus* spp. are more resistant to anti-microbial treatments (Thein et al., [@B55]; Barros et al., [@B5]). Pertaining to the oral cavity, the chief example of this type of association is *Candida*-associated denture stomatitis, wherein *Candida* coexists with several bacterial species, such as *S. aureus, E. coli*, and *Klebsiella* species (Thein et al., [@B55]). Thus, biofilms are difficult to eradicate and may cause frequent relapses and recurrent cases of OPC, especially in immunocompromised patients, such as AIDS patients. Several techniques have been advocated for the inhibition of biofilm formation, such as the use of silver nanoparticles, monoclonal antibodies, photodynamic therapy, enzymatic degradation of biofilm components, and the use of probiotic organisms to alter the structure, physiology, and behavior of mixed-species biofilms (Thein et al., [@B55]; Sardi et al., [@B48]).

Various drug interactions may play a role in the success of anti-fungal treatment
---------------------------------------------------------------------------------

The coexistence of epidemics of HIV, tuberculosis and malaria and opportunistic infections, such as those found in Africa, make drug interactions unavoidable to a great extent (Kigen et al., [@B23]). In one study, interactions involving nevirapine and ketoconazole revealed a 72% decrease in the ketoconazole concentration upon co-administration. The concurrent administration of fluconazole and nevirapine resulted in a 33% increase in nevirapine and thus was a probable cause of toxicity (Kigen et al., [@B23]).

Most tuberculosis regimens include rifampicin, which is a potent inducer of cytochrome P450 enzymes. The concomitant administration of rifampicin with fluconazole has led to noteworthy changes in the pharmacokinetic parameters of fluconazole, including a 39% increase in its elimination rate constant and a 28% shorter elimination half-life in AIDS patients (Panomvana Na Ayudhya et al., [@B4]). Similarly, the concurrent administration of rifampicin with ketoconazole and itraconazole markedly reduces the serum concentrations of these anti-fungal drugs (Swart and Harris, [@B51]). In one study, two patients co-infected with HIV-tuberculosis on both anti-tubercular drugs and azoles were reported to present for several months with recurrent episodes of OPC despite the presence of susceptible *Candida* strains, which could be explained by the previously discussed drug interactions (Mulu et al., [@B34]).

The occurrence of OPC in HIV-infected patients is determined by a multitude of factors, including the immune status and constitution of the individual, host cell-bacteria-mycological interactions, patient compliance, the response to anti-fungal therapy, anti-viral drug interactions, immune reconstitution, accessibility to standard treatment, and the severity of the immunocompromised status. Thus, the challenge of controlling and treating OPC in HIV patients can be met by identifying the *Candida* species and appropriate choice of the anti-fungal agent in combination with ART. Furthermore, the virulence factors and biofilm formation of the *Candida* organisms may be negated with exploration of the genetic pathways.

Diagnosis {#s4}
=========

The diagnosis of OPC is fairly clinical and is based on presentation with classical signs and symptoms of candidosis, although advanced microbiological assays are obligatory in non-responding cases. The diagnostic procedure for OPC cases in at-risk HIV patients is depicted in Figure [1](#F1){ref-type="fig"} (Thompson et al., [@B56]; Lortholary et al., [@B29]; Patil et al., [@B38]; Kaur et al., [@B22]).

![Diagnostic protocol for oropharyngeal candidiasis in HIV-positive patients.](fmicb-09-00980-g0001){#F1}

Management {#s5}
==========

Currently, several anti-fungal agents are available for OPC treatment (Table [4](#T4){ref-type="table"}). Topical therapies are implicated for milder presentations of OPC. Generally, fluconazole is the leading drug of choice and is notably effective with appropriate compliance with the HAART regimen (Vazquez, [@B58]; Lortholary et al., [@B29]; Patil et al., [@B38]). Among the other azoles, posaconazole is a superior option for therapy in cases with fluconazole-resistant *Candida* species (Vazquez, [@B58]; Katragkou et al., [@B21]). Itraconazole usage is complicated by its cross-resistance to fluconazole (Lortholary et al., [@B29]). The administration of ketoconazole is limited due to its adverse side effects and drug interactions with some HIV protease inhibitors (Vazquez, [@B58]). Echinocandins are effective due to their unique mechanisms of action and lack overlap resistance with the triazoles; thus, they are beneficial in refractory cases (Patil et al., [@B38]). Furthermore, although fluconazole is effective, anti-fungal prophylaxis for the prevention of OPC and esophageal candidiasis with this drug is not recommended, because very low attributable morbidity and mortality are associated with OPC. Additionally, fluconazole may lead to the development of drug-resistant *Candida* strains, although further acute therapy is highly effective and can cause significant drug-drug interactions ((Kanafani and Perfect, [@B19]; Lortholary et al., [@B29])).

###### 

Treatment of OPC (Vazquez, [@B58]; Lortholary et al., [@B29]; Patil et al., [@B38]).

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  **Anti--fungal agents**   **Form**          **Dosage**                      
  ------------------------- ----------------- ------------------------------- --------------------------------------------------------------------------
  First line                Nystatin\         Suspension (100,000 U/mL)\      4--6 mL four times daily for 7--14 days\
                            Clotrimazole\     Pastilles (200,000 U each)\     1--2 mL four times daily for 7--14 days\
                            Miconazole\       Oral troche (10 mg)\            1 five times daily for 7--14 days\
                            Fluconazole       Lauriad\                        Once daily for 7--14 days\
                                              Muco-adhesive buccal Tablets\   Once daily for 7--14 days\
                                              (50 mg)\                        (Apply to mucosal surface following detailed manufacturer instructions)\
                                              Tablet\                         1 tablet daily for 7--14 days\
                                              (100 mg−200 mg)\                10 mL once daily for 7--14 days
                                              Solution (10 mg/mL)\            
                                              (PO or I.V.)                    

  Second line               Itraconazole\     Capsule (200 mg) (PO)\          1 capsule daily for 28 days\
                            Posaconazole\     Solution (10 mg/mL) (PO)\       10--20 mL once daily\
                            Voriconazole      Tablet (400 mg) (PO)\           Daily in divided doses\
                                              Tablet (200 mg) (PO or I.V.)    2 tablets daily

  Refractory cases          Caspofungin\      I.V.\                           70 mg (loading dose) followed by 50 mg daily\
                            Micafungin\       I.V.\                           100--150 mg daily\
                            Anidulafungin\    I.V.\                           100 mg (loading dose) followed by 50 mg daily\
                            Amphotericin B\   Oral suspension\                500 mg every 6 h.\
                            Amphotericin B\   I.V.                            0.3 mg/kg once
                            deoxycholate                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------

Various alternative therapies have been suggested and investigated recently (Mehra et al., [@B31]). One such discovery includes chiloscyphenol A (extracted from Chinese liverworts), which shows promising fungicidal activity by inducing mitochondrial dysfunction and plasma membrane destruction in *C. albicans*. Furthermore, this drug exhibited potent activity in preventing biofilm formation by *C. albicans* and targeting cells within mature biofilms, including strains resistant to fluconazole (Zheng et al., [@B62]). Another study showed that all clinical *C. albicans* isolates were susceptible to the *Trachyspermum ammi* essential oil, which had a significant effect on fungal growth in the exponential phase (Sharifzadeh et al., [@B50]). Certain traditional Chinese medicinal herbs (crude extracts containing berberine, palmatine, allicin, pseudolaric acid A and B, magnolol, honokiol, and galangin) are known for their anti-*Candida* properties and are claimed to be decent choices for treating refractory OPC in AIDS patients (Liu et al., [@B28]). Other proposals recommended to counteract resistant *Candida* species include targeting of cationic peptides and various fungal virulence factors (Sharifzadeh et al., [@B50]).

Conclusion {#s6}
==========

To summarize, OPC remains fairly prevalent in HIV-infected patients in the present era, with a significant percentage of NCAC and resistant *Candida* species being reported. Currently, fluconazole remains the leading drug of choice. The therapeutic implications of genetic pathways in *Candida* biofilm formation have not been explored. With the development of molecular and nano-technologies, the mechanisms of drug resistance are acknowledged more precisely and have vast implications for the development of targeted drug therapies.
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